Advanced of diagnosis and treatment on gastrointestinal stromal tumors

doi:10.3877/cma.j.issn.1674-3946.2018.06.027

Abstract

Abstract:

After nearly 20 years of research, great achievements have been made in treatment of gastrointestinal stromal tumors(GIST). Surgery is still the primary treatment for patients with localized GIST. At present, the imatinib is the first-line therapy for advanced GIST. It remains controversial whether different genotypes are associated with alternative adjuvant treatment options. Results of more researches are expected to provide better guidance for clinical treatment in the future.

Key words: Gastrointestinal Stromal Tumors, Diagnosis, Surgical Procedures, Operative, Molecular Targeted Therapy

Zhepeng Zhang, Hongyan Zhu, Guannan Shan, Liping Duan. Advanced of diagnosis and treatment on gastrointestinal stromal tumors[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2018, 12(06): 535-537.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2018.06.027

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2018/V12/I06/535

References 29

[1]	Yan L, Zou L, Zhao W, et al.Clinicopathological significance of c－KIT mutation in gastrointestial stromal tumors：a systematic review and meta－analtsis[J]．Sci Rep, 2015, 5:13718-13718.
[2]	Jo VY, Fletcher CD.WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition[J]. Pathology, 2014, 46(2): 95-104.
[3]	Siow SL, Mahendran HA, Wong CM. Laparoscopic transgastic resection for intraluminal gastric gastrointestinal stromal tumors located at the posterior wall and near the gastroesophageal junction[J]．Asian J Surg, 2017, 40(5):407-414.
[4]	Joensuu H, Vehtari A, Riihim？ki J, et al.Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population－based cohorts [J]. Lancet Oncol, 2012, 13 (3) : 265-274.
[5]	Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours[J]．Histopathology, 2008, 53(3):245-266.
[6]	Corless CL, Schroeder A, Griffith D, et al.PDGFRA mutations in gastrointestinal stromal tumours: frequency, spectrum and in vitro sensitivity to imatinib[J]．J Clin Oncol, 2005, 23(23):5357-5364.
[7]	Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumours[J]．Science, 2003, 299(5607):708-710.
[8]	中国临床肿瘤学会胃肠间质瘤专家委员会．中国胃肠间质瘤诊断治疗共识(2018年版)[J]．肿瘤综合治疗电子杂质，2018，4(1):31-43.
[9]	Tajima S, Ohata A, Koda K, et al. Myxiod epithelioid gastrointestinal stromal tumor harboring an unreported PDGFRA mutation: report of a case and review of the literature[J]. Int J Clin Exp Pathol, 2015, 8(5):5821-5829.
[10]	Ricci R, Saragoni L．Everything you always wanted to know about GIST(but were afraid to ask) an update on GIST pathology[J]. Pathologica, 2016, 108(3):90-103.
[11]	Bareck E, Ba－Ssalamah A, Brodowicz T, et al. Gastrointestinal stromal tumors：diagnosis, therapy and follow－up care in Austria[J]. Wien Med Wochenschr, 2013, 163(5-6):137-152.
[12]	NCCN.The NCCN clincal practice guidelines in oncology: soft tissue sarcoma (version 2.2018)[EB/OL]. Fort Washington: NCCN, 2018[2018－03－27]. URL
[13]	李生栩，唐明灯，林端瑜，等.18F－FDG PET－CT显像评价胃肠间质瘤恶性潜能的价值[J]．中华肿瘤杂志，2017，39(11):821-827.
[14]	Langer C, Gunawan B, Schüler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours[J]．Br J Surg, 2003, 90(3): 332-339.
[15]	Blay JY, Le Cesne A, Cassier PA, et al. Gastrointestinal stromal tumors(GIST): a rare entity, a tumor model for personalized therapy, and yet different molecular subtypes[J]. Discov Med, 2012, 13(72):357-367.
[16]	DeMatteo RP, Ballman KV, Antonescu CR, et al. Long－term results of adjuvant imatinib mesylate in localized, high－risk, primary gastrointestinal stromal tumor: ACOSOG Z9000(Alliance) intergroup phase 2 trial[J]. Ann Surg, 2013, 258 (3) :422-429.
[17]	王荣，徐勇. 腹腔镜治疗大于5cm胃肠间质瘤的临床疗效与安全性分析[J/CD]．中华普通外科手术杂志(电子版), 2017，11(6):482-484.
[18]	宋树祥，陈平．改良腹腔镜经黏膜下隧道切除胃间质瘤临床分析[J/CD]．中华普通外科手术杂志(电子版), 2016，10(6):505-508.
[19]	ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow－up[J]. Ann Oncol, 2014, 25(Suppl 3): iii21-iii26.
[20]	Choi H. Response evaluation of gastrointestinal stromal tumors[J]. Oncologist, 2008, 13(Suppl 2):4-7.
[21]	Rossi S, Congedo T, Ricci R, et al. Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review[J]. J gastrointest Oncol, 2017, 8(1):E4-E9.
[22]	Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites [J]．Semin Diagn Pathol, 2006, 23(2):70-83.
[23]	Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumour [J]．Hum Pathol, 2008, 39(10):1411-1419.
[24]	Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence－free survival after complete surgical resection of localised primary gastrointestinal stromal tumor: a retrospective analysis [J]．Lancet Oncol, 2009, 10(11):1045-1052.
[25]	Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial[J]. JAMA, 2012, 307(12): 1265-1272.
[26]	Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of sunitinib(GRID): an international, multicentre, randomized, placebo－controlled, phase 3 tiral[J]. Lancet, 2013, 381(9863):295-302.
[27]	Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma level are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors [J]. J Clin Oncol, 2009, 27(19):3141-3147.
[28]	徐皓，马利林，徐为，等．胃肠间质瘤患者服药前后监测伊马替尼血浆浓度意义的中国多中心研究[J]．中华胃肠外科杂志，2016，19(11):1271-1276.
[29]	Yoo C, Ryu MH, Kang BW, et al.Cross－sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib[J]. J Clin Oncol, 2010, 28(9):1554-1559.

Please choose a citation manager

Content to export